Andrew Dunn is a senior biopharma correspondent, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. His reporting interests include AI's emerging role in biotech, cell and gene therapy, and how money and medicine mix. Based in New York City, he joined Endpoints News in 2023, previously reporting on biotech at Business Insider and BioPharma Dive. His work has been cited by news outlets including the Washington Post, CNN, and the New York Times. He’s also appeared on CNBC, C-SPAN, and MSNBC to discuss his work. Dunn graduated from the University of Maryland, College Park, majoring in journalism and economics.